Core Viewpoint - The company Jianxin Superconductor (688805.SH) has successfully launched on the STAR Market, focusing on the research, production, and sales of core components for medical MRI equipment, which constitute approximately 50% of the cost of MRI devices [1][4]. Group 1: Company Overview - Jianxin Superconductor was established on December 11, 2013, and is recognized as one of the earliest manufacturers in China to scale the production of high-field superconducting magnets [7]. - The company has developed a diverse product matrix, including 1.5T and 3.0T superconducting magnets, and is the largest independent supplier of superconducting magnets globally [7]. - Jianxin Superconductor has established strong partnerships with renowned MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, facilitating the global promotion of MRI devices [7]. Group 2: Financial Metrics - The IPO price was set at 18.58 CNY per share, with an institutional offering price of 18.89 CNY per share, resulting in a market capitalization of 3.115 billion CNY [4]. - The company’s earnings per share (EPS) is projected with a price-to-earnings (P/E) ratio of 61.97, compared to the industry average of 31.79 [4]. Group 3: Fundraising and Investment Plans - Jianxin Superconductor plans to invest raised funds in several projects, including a 600-unit production line for liquid helium-free superconducting magnets (2.75 billion CNY), a technical upgrade for high-field superconducting magnets (2.60 billion CNY), and the development of new superconducting magnets (2.40 billion CNY) [6]. Group 4: Market Risks - The company faces a high customer concentration risk, with the top five customers accounting for 73.75% to 83.43% of total revenue from 2022 to mid-2025, with Fujifilm being the largest customer [8].

Core Viewpoint - The company Jianxin Superconductor (688805.SH) is set to be available for subscription on the Sci-Tech Innovation Board, focusing on the research, production, and sales of core components for medical MRI equipment, which constitute approximately 50% of the cost of MRI devices [1][6]. Group 1: Company Overview - Jianxin Superconductor was established on December 11, 2013, and is one of the earliest manufacturers in China to produce high-field superconducting magnets on a large scale [6]. - The company has developed a diverse product matrix, including 1.5T zero-evaporation superconducting magnets and 3.0T zero-evaporation superconducting magnets, becoming the largest independent supplier of superconducting magnets globally [6]. - Jianxin Superconductor has established close partnerships with renowned MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, with over 50% of its products being sold to international markets [6]. Group 2: Financial Information - The initial offering price is set at 18.58 yuan per share, with an institutional quotation of 18.89 yuan per share, and the company's market capitalization is approximately 2.337 billion yuan [3]. - The company’s projected earnings per share (PE) ratio is 61.97, compared to the industry average of 31.79 [3]. - The company plans to invest approximately 2.75 billion yuan in a project to produce 600 sets of non-liquid helium superconducting magnets, which accounts for 35.48% of the total fundraising [5]. Group 3: Risks and Challenges - The company faces a high customer concentration risk, with the top five customers accounting for 73.75% to 83.43% of total revenue from 2022 to the first half of 2025, with Fujifilm being the largest customer [7]. - Although sales and gross profit from Fujifilm do not exceed 50%, any significant changes in the customer landscape or performance could adversely affect the company's profitability [7].

Core Viewpoint - The company Jianxin Superconductor (688805.SH) has initiated its subscription with an issue price of 18.58 yuan per share and a price-to-earnings ratio of 61.97 times, focusing on the research, production, and sales of core components for MRI equipment, which account for approximately 50% of the cost of MRI devices [1]. Group 1: Company Overview - The company specializes in the research, production, and sales of core components for medical MRI equipment, including superconducting magnets, permanent magnets, and gradient coils [1]. - The company has achieved breakthroughs in core technologies for superconducting magnets, permanent magnets, and gradient coils, ensuring the independence and controllability of core components in the domestic MRI industry [2]. Group 2: Product Development and Market Position - The company has developed a comprehensive product matrix in the superconducting field, including 1.5T and 3.0T zero-evaporation superconducting magnets, becoming the world's leading independent supplier of superconducting magnets [2]. - The company has closed a 20-year technology gap with international giants in zero-evaporation superconducting technology and has broken the long-standing monopoly of European, American, and Japanese manufacturers in the 1.5T product field since 2015 [2]. Group 3: Technological Advancements - The company has transitioned from a follower to a leader in the next-generation helium-free superconducting technology, achieving a fully helium-free superconducting magnet and being recognized as the "international first set of equipment" by the Zhejiang Provincial Economic and Information Technology Department in 2021 [3]. - The company is the largest supplier of MRI permanent magnets globally, providing high-quality products that are economically viable and suitable for grassroots medical systems [3]. Group 4: Financial Performance - The company reported revenues of approximately 359 million yuan, 451 million yuan, 425 million yuan, and 252 million yuan for the years 2022, 2023, 2024, and the first half of 2025, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, 55.78 million yuan, and 31.92 million yuan during the same periods [4]. - As of June 30, 2025, the total assets of the company were approximately 688.99 million yuan, with a debt-to-asset ratio of 29.22% [5].

Group 1 - The core point of the article is the approval by the China Securities Regulatory Commission for Ningbo Jianxin Superconducting Technology Co., Ltd. to conduct its initial public offering (IPO) on the Shanghai Stock Exchange, with a fundraising target of 865 million yuan [1] - Jianxin Superconducting primarily engages in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils [1] - The company has developed a diverse product matrix in the superconducting field, including 1.5T zero-evaporation superconducting magnets, 1.5T liquid helium-free superconducting magnets, 3.0T zero-evaporation superconducting magnets, and open zero-evaporation superconducting magnets, making it the leading independent supplier of superconducting magnets in the global MRI industry [1]

Core Viewpoint - Ningbo Jianxin Superconductor Technology Co., Ltd. has successfully passed the IPO review for the Sci-Tech Innovation Board, positioning itself as the world's largest independent supplier of superconducting magnets for MRI equipment [1][2] Group 1: Company Overview - Jianxin Superconductor's IPO application was approved on October 21, with its review status updated to "submitted for registration" [1] - The company ranks fifth globally and second domestically in terms of market share for superconducting magnets used in MRI equipment, based on installed capacity [1] Group 2: Market Position and Technology - The company has closed a 20-year technology gap with international giants in the field of zero-evaporation superconducting technology, enhancing product performance and cost competitiveness through design and process innovation [2] - Jianxin Superconductor is one of the earliest manufacturers in China to scale up the production of high-field superconducting magnets, breaking the long-standing monopoly of European and Japanese manufacturers since 2015 [2] Group 3: Financial Performance - The company's revenue for the years 2022 to 2024 and the first half of 2025 is as follows: - 2022: 35.89 million yuan - 2023: 45.06 million yuan - 2024: 42.55 million yuan - 2025 (first half): 25.21 million yuan [2] - Net profit figures for the same periods are: - 2022: 3.46 million yuan - 2023: 4.87 million yuan - 2024: 5.58 million yuan - 2025 (first half): 3.19 million yuan [2] Group 4: Partnerships and Industry Impact - The company has established close partnerships with well-known MRI equipment manufacturers, including Fujifilm, GE Healthcare, and United Imaging Healthcare, contributing to the domestic MRI industry's core component supply [2]

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. has received approval for its IPO application on the Sci-Tech Innovation Board, with its review status updated to "submitted for registration" as of October 21 [1] Group 1: Market Position and Competitiveness - In terms of installed capacity, Jianxin Superconducting ranks fifth globally and second among domestic companies in the MRI superconducting magnet market for 2024, making it the largest independent supplier of superconducting magnets worldwide [1] - The company has established a comprehensive product matrix in the superconducting field, including 1.5T zero-evaporation superconducting magnets and 3.0T zero-evaporation superconducting magnets, becoming the top independent supplier in the global MRI industry [3] - Jianxin Superconducting has closed a 20-year technology gap with international giants in the zero-evaporation superconducting technology field and has continuously improved product performance and cost competitiveness through design and process innovation [3] Group 2: Financial Performance - The company's revenue for the periods from 2022 to 2024 and the first half of 2025 are as follows: 358.93 million yuan, 450.64 million yuan, 425.50 million yuan, and 252.10 million yuan respectively [4] - The net profit for the same periods is reported as 34.63 million yuan, 48.73 million yuan, 55.78 million yuan, and 31.92 million yuan respectively [4] Group 3: Strategic Partnerships - Jianxin Superconducting has established close cooperative relationships with well-known MRI equipment manufacturers both domestically and internationally, including Fujifilm Holdings, GE Healthcare, and United Imaging Healthcare [3]